Headache

Headache

Barriers to appropriate care in chronic and episode migraine: findings of the CaMEO study 8:14
Barriers to appropriate care in chronic and episode migraine: findings of the CaMEO study
Dawn Buse • 19 Apr 2021
Depression and anxiety worsen headache-related disability independent of headache frequency 6:39
Depression and anxiety worsen headache-related disability independent of headache frequency
Dawn Buse • 19 Apr 2021
Rapid progress in the migraine space 5:47
Rapid progress in the migraine space
Dawn Buse • 19 Apr 2021
BonTriage: an AI tool to conquer headache 6:55
BonTriage: an AI tool to conquer headache
Robert Cowan • 30 Apr 2021
Impact of sex and race on the migraine patient’s journey 3:13
Impact of sex and race on the migraine patient’s journey
Robert Cowan • 30 Apr 2021
Trends in migraine treatment 2:25
Trends in migraine treatment
Robert Cowan • 30 Apr 2021
Microvascular complications of CGRP antagonists for migraine patients with Raynaud’s phenomenon 3:00
Microvascular complications of CGRP antagonists for migraine patients with Raynaud’s phenomenon
Ilana Breen • 27 Apr 2021
Bringing mindfulness into clinical practice for migraine 1:32
Bringing mindfulness into clinical practice for migraine
Rebecca E. Wells • 20 Apr 2021
Mindfulness meditation vs. headache education for migraine treatment 5:21
Mindfulness meditation vs. headache education for migraine treatment
Rebecca E. Wells • 20 Apr 2021
How does mindfulness induce pain relief in migraine? 1:31
How does mindfulness induce pain relief in migraine?
Rebecca E. Wells • 20 Apr 2021
Migraine is one of the principal causes of disability worldwide 1:09
Migraine is one of the principal causes of disability worldwide
Susan Hutchinson • 21 Apr 2021
The stigma of migraine in women’s life 2:06
The stigma of migraine in women’s life
Susan Hutchinson • 21 Apr 2021
STOP 301: non-oral INP104 for the acute treatment of migraine 1:34
STOP 301: non-oral INP104 for the acute treatment of migraine
Jessica Ailani • 18 Apr 2021
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention 3:02
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention
Jessica Ailani • 18 Apr 2021
Ubrogepant safety by age, gender and race 1:06
Ubrogepant safety by age, gender and race
Jessica Ailani • 18 Apr 2021
Rimegepant to treat acute migraine in patients with cardiovascular risk factors 2:36
Rimegepant to treat acute migraine in patients with cardiovascular risk factors
Susan Hutchinson • 21 Apr 2021
The content of VJNeurology is intended for healthcare professionals